Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy

Christophe Duponta Pediatric Gastroenterology Department, Marcel Sembat Clinic, Ramsay Group, Boulogne Billancourt, FranceCorrespondence[email protected]
View further author information

A. Wesley Burksb Division of Pediatric Allergy and Immunology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, USAView further author information

David M. Fleischerc Children’s Hospital Colorado, Section of Allergy and Immunology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USAView further author information

Katharine J. Beed DBV Technologies, Basking Ridge, NJ, United StatesView further author information

Sarita Chainanid DBV Technologies, Basking Ridge, NJ, United StatesView further author information

Hugh A. Sampsond DBV Technologies, Basking Ridge, NJ, United States;e Department of Pediatrics, Division of Allergy & Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information

Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date